Want to join the conversation?
Global biopharmaceutical company $BXLT's Singapore facility which received regulatory approval from the European Medicines Agency in Jan. 2014, has received U.S. FDA approval to produce ADVATE, a antihemophilic factor bulk drug substance, which is used to treat hemophilia A (congenital factor VIII deficiency) in children and adults.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.